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Objectives. To determine if therapy with pioglitazone HCl and tretinoin could slow disease progression in patients with ALS. Levels
of tau and pNFH in the cerebrospinal fluid were measured to see if they could serve as prognostic indicators. Methods. 27 subjects
on stable doses of riluzole were enrolled. Subjects were randomized to receive pioglitazone 30mg/d and tretinoin 10mg/BID for
six months or twomatching placebos. ALSFRS-R scores were followedmonthly. At baseline and at the final visit, lumbar punctures
(LPs) were performed to measure cerebrospinal fluid (CSF) biomarker levels. Results. Subjects treated with tretinoin, pioglitazone,
and riluzole had an average rate of decline on the ALSFRS-R scale of −1.02 points per month; subjects treated with placebo and
riluzole had a rate of decline of −.86 (P = .18). Over six months of therapy, CSF tau levels decreased in subjects randomized to
active treatment and increased in subjects on placebo. Further higher levels of pNF-H at baseline correlated with a faster rate of
progression. Conclusion. ALS patients who were treated with tretinoin and pioglitazone demonstrated no slowing on their disease
progression. Interestingly, the rate of disease progression was strongly correlated with levels of pNFH in the CSF at baseline.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating progres-
sive neurodegenerative disease. ALS affects people of all ages
and both sexes with a reported annual incidence of 1-2 in
100,000. 90% of the cases of ALS occur sporadically, while
10% of patients with ALS have a family history of the disease.
The course of ALS is progressive and the majority of the
patients succumb within 2–5 years from disease onset. At
present, there is no effective therapy for ALS, nor is there a
single known cause. After several decades of trials, only one
drug with modest disease modifying efficacy, riluzole, has
been developed. Therefore, it is imperative for clinical trials
to be designed and analyzed quickly. With the disease being
rapidly fatal, eligible patients are difficult to enroll in studies,
yet the need for compassionate care is essential.
Recent discoveries have identified several single-nucle-
otide polymorphisms (SNPs) in the anaplastic lymphoma
kinase (ALK) gene which have been associated with sporadic
ALS [1, 2]. In addition, reduced levels of ALK mRNA have
been reported in ALS patients. In 2003, Dangond et al.
used spinal cord tissue and microarray analysis and observed
a 9-fold downregulation of ALK mRNA in ALS patients
[3]. They further substantiated this finding by verifying the
change in ALK expression with real-time quantitative RT-
PCR. Midkine (MK), a ligand for ALK, was also found to be
decreased in patients with sporadic ALS [4].
The expression of MK is induced by retinoic acid signal-
ing, and in addition to activating ALK, MK has the ability to
activate neurite outgrowth and increase angiogenesis. It has
also been shown that retinoic acid inducible genes improve
survival in the G93A-SOD1 transgenic mouse model of
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ALS [5]. Further, two of the best-studied and most beneficial
gene therapies in animal models of ALS, insulin growth
factor (IGF), and vascular endothelial growth factor (VEGF),
are induced by retinoic acid.
The importance of retinoic acid responsive genes in
modulating spinal motor neuron degeneration has been
demonstrated in rodentmodels [5]. It was demonstrated that
astrocytosis, accumulation of neurofilament, motor neuron
loss, and a significant loss of motor neuron retinoic acid
receptor expression were observed in the lumbar spinal
cord of vitamin A deficient animals. Recent findings of the
role of retinoid signaling in the pathogenesis of ALS have
gained momentum with the development of gene expression
analysis in spinal cord from animal models and humans
with disease [6]. Retinoid signaling, while crucial in the
development and maintenance of the central nervous system
(CNS), may also contribute to regenerative mechanisms that
occur after CNS injury or disease to mediate plasticity and
repair. Additional evidence supporting the role of retinoid
signaling comes from proteomic studies of cerebrospinal
fluid (CSF). Reduced levels of transthyretin (TTR) and
increased posttranslational modifications to TTR have been
detected in the CSF of ALS patients [7]. TTR functions to
transport and deliver retinol to cells of the CNS. Altered
protein levels for multiple members of the retinoid signaling
pathway have been detected in spinal cord tissue of ALS
patients [4]. Data also suggests that stimulating retinoic
acid receptors (RARs) are neuroprotective and therefore
pharmacologic agents that target these nuclear receptors may
be of value in slowing the progression of ALS [8].
Retinoic acids have been studied extensively in various
models of the injured nervous system. These studies have
shown that retinoic acids may have three distinct, impor-
tant roles in ALS. (1) Retinoids may be neuroprotective
and support axonal growth. (2) They may modulate the
inflammatory reaction by microglia and macrophages. (3)
Theymay regulate glial cell differentiation [9]. These findings
suggest that retinoid signaling might slow the progression of
sporadic ALS.
Another potential etiology of ALS, as well as other
neurodegenerative diseases, is neuroinflammation. In the
last decade, the neuroprotective properties of proliferator-
activated receptor gamma (PPAR gamma) agonists have
received increasing attention and have been examined in
a number of preclinical models of neurodegenerative con-
ditions, including Parkinson’s disease, Alzheimer’s disease,
cerebral ischemia, ALS, and spinal cord injury. These diseases
share an excess of neurotoxic, proinflammatory immune
responses as compared to anti-inflammatory microglia or
T suppressor cell responses [10]. Therefore, therapeu-
tic strategies designed to modulate microglial activation,
reinstating the physiological shift toward less neurotoxic
phenotypes, may represent a neuroprotective goal. PPAR
gamma agonists act as potent anti-inflammatory drugs and
have been studied in G93A-SOD1 transgenic mice, a mouse
model of ALS. These studies demonstrate that pioglitazone
HCl-treated transgenic mice have improved muscle strength
and body weight, exhibit a delayed disease onset, and
survive significantly longer than nontreated G93A-SOD1
mice. Quantification of motor neurons of the spinal cord
at day 90 revealed complete neuroprotection by pioglitazone
HCl, whereas non-treated G93A-SOD1 mice had lost 30%
of motor neurons. This was paralleled by preservation of the
median fiber diameter in the quadriceps muscle, indicating
not only morphological, but also functional protection of
motor neurons by pioglitazone HCl. Activated microglia
were significantly reduced at sites of neurodegeneration in
pioglitazone HCl treated G93A-SOD1 mice, as were the
protein levels of cyclooxygenase-2 and inducible nitric oxide
syntheses [11].
While a PPAR gamma and a retinoic acid agent could be
studied individually, a drug cocktail may offer the best chance
of attaining a significant reduction in disease progression,
utilizing currently available FDA-approved agents. There-
fore, a trial of riluzole, in combination with pioglitazone
HCl, a PPAR gamma agonist, and tretinoin, a retinoid, was
undertaken.
For the past few years, there has been growing evidence
that throughout the course of ALS, proteins are released from
injured/dying axons and cell bodies that can be detected
in the CSF. Developing biomarkers for ALS has emerged
as one of the most urgent needs in the search for effective
treatments, because these proteins may provide prognostic
indicators for rate of disease progression, or theymay be used
to monitor therapeutic efficacy of drugs that reduce motor
neuron injury and/or cell death. Of these proteins, cytoskele-
tal proteins including phosphorylated neurofilament heavy
chain (pNFH) and tau have been shown to be elevated
in the CSF of neurodegenerative diseases and proposed as
biomarkers for ALS [12–15] and neurofilament aggregates
have been observed in spinal cord motor neurons of ALS
patients [16]. Levels of pNFH were shown to be significantly
increased in the CSF of ALS patients when compared to
disease mimics [17, 18]. Therefore, we also measured the
levels of these candidate biomarkers before treatment and
after six months of drug therapy.
2. Methods and Materials
2.1. Subjects. Twenty-eight subjects, who met the El Escorial
criteria for probable or definite ALS, between the ages of
18 and 85 and were on a stable dose of Rilutek for at
least 30 days prior to the start of the study, were screened.
Women of childbearing potential were using an effective
method of birth control and had a negative pregnancy
test prior to randomization. Subjects who had a history of
liver disease, severe renal failure, diabetes, coronary heart
disease, clinically significant EKG abnormality at screening
or intolerance to Riluzole, or any other comorbid condition
which would make completion of the trial unlikely or
a FVC of less than 70% were excluded. All procedures
were approved by the Western Institutional Review Board
(WIRB) and were conducted with the understanding and
consent of all subjects. Informed consents were obtained
from all individuals in accordance with institutional review
board requirements prior to the start of any study-related
procedures at screening.
Neurology Research International 3
2.2. Study Procedures. Prior to enrollment, potential subjects
were evaluated, screened, and consented. A medical history
was completed and a physical and neurological exam was
performed. An EKG was performed to rule out significant
cardiac abnormalities and a FVC test was completed for
eligibility. Subjects who met all inclusion criteria and met no
exclusionary criteria underwent a lumbar puncture and 6 cc
of CSF were collected for analyzing specific proteins such as
tau and pNF-H at screening. Subjects were also required to
fast prior to screening and prior to every subsequent visit.
This ensured accurate results for glucose and lipid testing.
Amylase, lipase, and a comprehensive metabolic panel were
also monitored monthly. Eligible subjects came back for
randomization 2 months after screening. This two-month
run-in phase was designed to see if we could determine
an individual patient’s baseline rate of progression. Subjects
randomized to drug received 30mg/day of pioglitazone
HCl and 10mg BID of Tretinoin. Subjects randomized to
placebo receivedmatching placebos for pioglitazone HCl and
tretinoin. Drug andmatching placebo were manufactured by
The Apothecary Shop in Scottsdale, Arizona. An unblinded
member of PNA’s study team randomized subjects based on
screening number and dispensed the appropriate medication
to subjects. The PI, study coordinator and the patient
were blinded during treatment. Subjects who experienced
intolerable side effects abated the tretinoin but continued
taking pioglitazone HCl (N = 5). 2 patients on placebo
reported side effects and had the placebo matching the
tretinoin stopped. Subjects were seen 8 weeks after screening
for randomization then again at months 1, 2, 3, 4, and 6. The
primary outcome measurement, ALSFRS revised (ALSFRS-
R), was administered and assessed by the same rater at each
visit to insure reproducibility and reduce variability. The last
recorded ALSFRS-R score was subtracted from their baseline
ALSFRS-R score and was divided by the number of months
that the subjects were on treatment to determine a monthly
change in ALSFRS-R score. Secondary outcome measures
were evaluated at baseline then again at the final visit (after 6
months of treatment), which included lumbar punctures for
assessment of protein biomarkers of axonal injury.
2.3. CSF Collection and Analysis. Lumbar punctures were
performed at baseline and the final visit. Samples were
collected at a similar time of the day for all subjects. 6 ccs
of cerebrospinal fluid (CSF) were collected into a low-bind
tube and frozen in a −80◦C freezer for storage. All samples
were coded to maintain patient confidentiality. Total protein
concentrations were determined using the BCA Protein
Assay Kit (Thermo Scientific, Waltham, MA). Levels of
candidate biomarkers were determined using commercial
ELISA kits to total tau (Invitrogen, Carlsbad, CA) and phos-
phorylated neurofilament heavy chain (pNF-H) (BioVendor
Research and Diagnostic Products, Candler, NC) following
manufacturer instructions. All samples were analyzed in
triplicate within each experiment, and all experiments were
performed at least twice on separate days.
Patient disease progression was monitored by decline
in the revised ALS functional rating scale (ALSFRS-R) and
correlated to CSF protein levels using the Pearson correlation
test. These correlations were stratified into placebo, tretinoin
plus pioglitazone HCl, and pioglitazone HCl-alone treat-
ment groups. For group comparisons, nonparametricMann-
Whitney t-test was used to determine statistical significance,
followed by paired t-test for pairwise comparisons within
individual patients between baseline and final values. For
all data analysis, we set a significance level of P < 0.05. All
statistical analysis was performed using GraphPad Prism 5.0
software (GraphPad Software Inc. La Jolla, CA).
3. Results
3.1. Study Population. Twenty-eight subjects were screened,
but only 27 enrolled in this double blinded, placebo
controlled study (12 females and 15 males). Subjects were
randomized in a 2 : 1 fashion to tretinoin and pioglitazone
HCL or placebo. Subjects who were randomized to the drug
arm received tretinoin at 10mg BID and pioglitazone HCL
at 30mg QD. Subjects who were randomized to the placebo
arm received matching placebos for both medications.
Baseline demographics and functional indices are as noted:
average FVC was 82%, average time from symptom onset
was 5 months, the average baseline ALSFRS-R score was 37,
and the mean age was 58. There was no significant difference
between the placebo and the active arm in any of these
demographic features. The average time from symptom to
onset to study entry was 18 months for placebo and 24
months for the active arm.
3.2. Effect of Therapy on Disease Progression. There were
22 subjects who completed more than three months of
therapy and these were all included in an intent-to-treat
analysis. Of these 22 subjects, 16 were randomized to drug
and 6 to placebo. There were five subjects in the active
arm who experienced intolerable side effects (1 extreme
dry skin, 3 felt they were progressing faster, and 1 had
increased fatigue). All five subjects stopped taking the pill
corresponding to the tretinoin and two of the five subjects’
symptoms abated shortly after discontinuation. 3 patients
felt they were progressing more rapidly on therapy and this
continued even after stopping all study medication. These
patients had a baseline rate of progression in the run-in phase
of 1.83, and once starting therapy, their monthly change in
ALSFRS-R was 1.75 (P = 0.71). The 16 subjects who were
on active drug and completed at least 3 months of therapy
lost on average −1.02 compared to their baseline rate of
progression of −1.13 (P = 0.13). The 6 subjects on placebo
averaged a loss of −0.86 compared to their baseline rate of
progression of 1.11 (P = 0.38).
3.3. CSF Biomarkers. The baseline levels of tau in the CSF
differed significantly between the two groups. The average
tau level for the active armwas 300.7 pg/mL (n = 10) as com-
pared to 126.5 pg/mL for the placebo arm (n = 4) (Figure 1).
After six months of therapy the active arm (n = 10)
demonstrated a 26% decline in the tau values to 223.9 pg/mL
(P = 0.22), whereas the placebo arm (n = 4) demonstrated
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Figure 1: Levels of tau in CSF of patients in active arm ver-
sus placebo arm at baseline and after six months of therapy.
(∗Significant difference in levels of tau at baseline between the
two groups, P = 0.02 by Mann-Whitney t-test). Error bars denote
standard deviation.
a 29% increase in tau values (P = 0.48). We did not detect a
significant change within individuals over time using a paired
t-test (data not shown). There was also no relationship
between the levels of tau and patient rate of progression.
The CSF levels of pNFH did not differ between the active
and placebo groups and there was no significant change
during the course of therapy for individual patients (data not
shown). However there was a strong statistical relationship
between the baseline value of pNFH and the rate of disease
progression (Figure 2). Patients who progressed faster than
0.5 points per months on the ALSFRS-R had an average
level of 2860 pg/mL compared to patients who progressed
less than 0.5 points per month who averaged 1331 pg/mL
(P = 0.03).
3.4. Survival. There were 18 subjects who completed the
entire 6 months of therapy. One patient dropped out prior
to being randomized, and five subjects withdrew after at
least two months of therapy. Of the five who withdrew,
3 were on treatment and 2 were on placebo. During the
course of the study, 4 subjects died (2 on active drug and 2
on placebo). Three of the four subjects died of respiratory
complications and one committed suicide (they had no
prior history of depression or suicidal ideation). The average
baseline ALSFRS-R score for the subjects who died was 33,
which was lower than the average baseline value (38) for
those that completed the study (P = 0.222).
3.5. Compliance and Safety. Compliance was measured
through drug accountability. All subjects were required to
return unused medication at each visit. Drug was accounted
for by the amount of drug returned subtracted from drug
dispensed based on how much drug should have been taken.
Tretinoin administered at 10mg bid was tolerated by 69%
∗
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Figure 2: Average pNFH levels in patients who lost <0.5 ALSFRS-
R points per month compared to patients who lost >0.5 ALFRS-R
points permonth. (∗Significant difference between the slow and fast
progressors, P = 0.03 by Mann-Whitney t-test). Error bars denote
standard deviation.
and pioglitazone HCl was tolerated by 88% of the subjects
randomized to active treatment. There was a 19% dropout
rate due to adverse events or intolerability. A DSMB board
met shortly after the first four patients were randomized,
then every six months thereafter to assure safety, tolerability,
and study compliance. Other than one suicide, no other
serious events were recorded. At the interim analysis, the
majority of subjects tolerated the medication well. Shortly
after the last patient completed 1 month on study drug, the
FDA reported that the use of pioglitazone HCl increased
the rate of bladder cancer. Subjects who were actively taking
pioglitazone HCl were contacted and were given the option
to withdraw or discontinue use. Everyone continued on
treatment, but we felt, in the best interest of others, to stop
enrollment at 28 instead of the planned 30.
4. Discussion
This initial phase II trial of tretinoin and pioglitazone HCl
used in combination with riluzole showed no significant
effect on the rate of disease progression. One of the
weaknesses of this study was the small sample size. However,
the trial was designed to see if there was a significant
and dramatic effect on disease progression. This type of a
dramatic treatment effect is the primary goal in ALS trials, as
another agent with minimal efficacy is not desirable. If some
treatment effect had been found, then this trial would have
formed the basis for a larger phase II/III trial. Unfortunately,
the results demonstrated lack of efficacy with tretinoin
and pioglitazone HCl. Another weakness is the use of two
experimental drugs and the use of riluzole in all subjects.
These were compromises that were intentionally made to
address limitations such as the cost of conducting a larger
trial, the difficulty of recruiting subjects, and the difficulty of
asking patients with ALS to forgo the only available therapy.
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Among the 16 subjects randomized to active treatment
who completed more than 3 months of therapy, the average
decline in ALSFRS-R was −1.02 points per month. This
was higher than the rate of decline in subjects randomized
to placebo (−0.86); however, this was not significant (P =
0.63). There was also no significant difference between the
rate of progression observed during the two-month run-in
phase and the rates of progression seen in the placebo and
active arms during therapy.
The results from our CSF biomarker studies suggest a
correlation between the baseline level of pNFH and disease
progression. Subjects who progressed at rates faster than
−0.5 points per month on the ALSFRS-R scale had levels
of pNF-H that averaged 2860 pg/mL, while subjects who
progressed at less than −0.5 points per month averaged
1331 pg/mL (P = 0.03) (Figure 2). Our results suggest that
elevated levels of pNFH in the CSF may serve as a candidate
biomarker for injury or death of motor neurons in patients
with ALS. Thus higher CSF levels of pNFH may indicate
patients with faster disease progression, a finding that
mirrors results of a prior clinical study with memantine [19].
Subjects randomized to combination therapy had a non-
statistically significant decrease in tau CSF levels during the
course of treatment (an average decrease of 76.8 pg/mL) and
26% decrease (P = 0.167) compared to subjects on placebo
whose levels increased (average increase of 44.91 pg/mL and
29% increase (P = 0.412) (Figure 1). These results may be
skewed as there was a significant difference in baseline levels
of tau between the active and placebo groups, such that the
active arm had 2.4 times the amount of tau at baseline.
Patients were not stratified based on these levels, thus this
difference was purely coincidental. Therefore, the decline in
the active arm and the increase in placebo arm may simply
be a regression towards the mean. Further, levels of tau did
not correlate to the rate of clinical progression as measured
by the ALSFRS-R (data not shown).
5. Conclusion
In summary, our randomized, placebo-controlled trial com-
bining riluzole with tretinoin and pioglitazone HCl failed to
alter clinical disease progression over a 6-month time course.
CSF-based biomarkers also failed to exhibit significant
changes due to drug treatment, though initial levels of pNFH
correlated to rate of disease progression. However, it remains
possible that other drug treatments that target these same
biochemical pathways may be beneficial for ALS.
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